Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 22Terminated 8Unknown 3Recruiting 3Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 55Gastrointestinal 10CNS 9Tumor-Agnostic 3Breast 2Sarcoma 1Other solid neoplasm 1Other neoplasm 1Head & Neck 1

Conditions

Neoplasms 3Neoplasm Metastasis 1

Interventions

Radiotherapy 9Drug Therapy 9Cisplatin 9Gemcitabine 8Docetaxel 7Carboplatin 7Blood Specimen Collection 7Nivolumab 6Fluorouracil 6pembrolizumab 5Pemetrexed 5Capecitabine 5Surveys and Questionnaires 4Positron Emission Tomography Computed Tomography 4Paclitaxel 4Oxaliplatin 4Exercise 4Everolimus 4Data Collection 4Cetuximab 4indibulin 3icotinib 3Vincristine 3Trastuzumab 3Standard of Care 3Radiosurgery 3Neoadjuvant Therapy 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Injections 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Erlotinib Hydrochloride × Tumor-Agnostic × Clear all
NCT05904457 2023-06-15

BRISK

Asan Medical Center

Phase 2 Unknown
32 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Shanghai Changzheng Hospital

Phase 2 Unknown
300 enrolled
Tumor-Agnostic

Neoplasms

NCT00591383 2012-07-19

Phase I Study of Indibulin in Combination With Erlotinib in Advanced Solid Tumors

Alaunos Therapeutics

Phase 1 Unknown
10 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡